Acadia : We’re looking forward to connecting with the medical...

Acadia :

We’re looking forward to connecting with the medical genetics community from around the world at the 2025
@TheACMG
Annual Clinical Genetics Meeting where we will be presenting our findings in #RettSyndrome. Learn more and register: https://bit.ly/3QNnRTo



Neuren will also be there:



Neuren (NEU) – ASX Announcement 22 January 2025
Neuren Presentations at the ACMG Annual Clinical Genetics Meeting 2025
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced the acceptance of three
abstracts for presentation at the 2025 American College of Medical Genetics and Genomics (ACMG)
Annual Clinical Genetics Meeting, being held on 18–22 March 2025, in Los Angeles.
Details of the presentations are as follows:
“NNZ-2591, a Synthetic IGF-1 Metabolite Analog: Phase 2 Clinical Trial Results for Children and
Adolescents with Pitt Hopkins Syndrome”
• Presentation Type: Platform (O38)
• Date/Time: Thursday, 20 March – 1:30 PM (Platform Session 2)
“The Evolving Genetic Landscape of Phelan-McDermid Syndrome and Implications for Diagnostics”
• Presentation Type: Poster (P672)
• Date/Time: Friday, 21 March– 10:30-11:30 AM – Exhibit Hall A
“Safety, Efficacy, and Exposure-Response of NNZ-2591, a Synthetic Analog of an IGF-1 Metabolite, for
Phelan-McDermid Syndrome in Children and Adolescents”
• Presentation Type: Poster (P166)
• Date/Time: Friday, 21 March – 10:30-11:30 AM – Exhibit Hall A
All ACMG Annual Clinical Genetics Meeting content to be presented or published is embargoed until the
time of the actual conference presentation. Posters will be embargoed until Wednesday, 19 March at
5:00 pm PT.
Neuren Chief Medical Officer Liza Squires M.D. commented: “We are very pleased to have three
presentations at ACMG this year which highlight our programs to develop NNZ-2591 as a much-needed
treatment for Phelan-McDermid syndrome and Pitt Hopkins syndrome. The presentations address the
evolving diagnostic landscape in Phelan-McDermid syndrome, and the encouraging results achieved in
our Phase 2 trials.”